Acorda Therapeutics® is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda’s marketed products include ZANAFLEX CAPSULES® (tizanidine hydrochloride) and ZANAFLEX® (tizanidine hydrochloride) tablets. ZANAFLEX CAPSULES and ZANAFLEX are short-acting drugs approved for the management of spasticity. Because of the short duration of effect, treatment should be reserved for those daily activities and times when relief of spasticity is most important. The most frequent adverse events with these products are dry mouth, sedation, asthenia, and dizziness, and are most often considered mild to moderate. For full prescribing information click here.

On January 22, 2010 the FDA approved AMPYRA™ (dalfampridine). AMPYRA, which was previously referred to as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously called fampridine. For more information on AMPYRA, click here.

Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain through its preclinical pipeline.